Just like the novel coronavirus itself, the emergence of so-called long COVID has surprised both the patients who couldn’t shake their symptoms and the clinicians who have struggled to provide effective treatments. Now, as the U.S. looks to move past the pandemic, there remain unanswered questions about how this fallout from the virus might hamper some workers and for how long. These uncertainties could have important implications for workers’ compensation. By some measures, one in four patients who get COVID-19—even those with mild or asymptomatic cases—will experience subsequent symptoms that range from muscle and nerve pain to breathing difficulties to anxiety and depression. The scope of the challenge will require providers and employers to better understand the nature of the conditions, their origins, and the best paths for treatment. Watch this on-demand webinar to learn more about long COVID and the implications for workers and employers.
More stories
Supporting an Aging Workforce Through Ergonomics
As more employees work later into life, the risk of workplace injuries—especially musculoskeletal disorders—is on the rise. This article explores how ergonomic strategies can help risk managers protect older workers, cut injury-related costs, and maintain productivity. You'll learn why ergonomics matters, what interventions work, and how to adapt jobs in industries most affected by age-related injury risk.
Three Ways to Eliminate Chaos in the Auto Casualty Claims Process
Discover practical strategies to overcome auto claims complexity and rising costs.
Ask The Pharmacist: CGRP Therapies for Migraine Management in Workers' Compensation
Migraines affect around one out of every six Americans in the adult population and can significantly impact workplace productivity and quality of life. For adjusters managing claims involving chronic or post-traumatic migraines, understanding emerging medication options can be the key to approving care that drives real recovery.
Migraine Medication Trends in Work Comp
Join Tom Kerr as he interviews Nikki Wilson, Senior Director of Clinical Pharmacy Services to dig into part one of our annual drug trends series. In this short video they’ll discuss standout trends from our most recent data focusing on migraine medications.
Calculating the Value of Evidence-Based PT
Placing the term “evidence-based” before a medical treatment would seem to give it instant credibility. But is this phrase simply a marketing phrase or is their true meaning behind it? In this Enlyte Envision podcast, Kim Radcliffe, DHA, MHA, PT, Senior Vice President of Product Management, helps us better understand evidence-based physical therapy and its true impact on recovery and claim costs.
Workers’ Compensation Institute (WCI) 2025 Conference
Enlyte is proud to return as an Elite Sponsor at the 2025 Workers' Compensation Institute (WCI) Conference in Orlando, Florida—th